Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a saline laxative and for bowel preparation.
## Primary Indications
* Bowel evacuation prior to colonoscopy, sigmoidoscopy, or radiologic examination.
* Relief of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** Typically a single dose of 2.25 ounces (66 mL) administered rectally. Some protocols may recommend a second dose 10-12 hours later. Consult specific institutional bowel preparation guidelines.
* **Constipation:** Typically 1 dose (2.25 oz or 66 mL) administered rectally as a single dose. May be repeated as needed but not more than once in 24 hours.
## Pediatric Dosing
* **Children 2-11 years:** 1.125 ounces (33 mL) administered rectally as a single dose.
* **Children under 2 years:** Use is generally not recommended due to increased risk of toxicity. Consult a pediatrician for alternative options.
## Dose Adjustments
* No specific dose adjustments for renal or hepatic impairment are established. Caution is advised due to potential for electrolyte imbalances.
## Contraindications
* Congestive heart failure, ascites, significant renal impairment, congenital megacolon, intestinal obstruction, acute inflammatory bowel disease, perforated bowel.
* Patients with ileostomy or colostomy.
* Children under 2 years of age.
* Concomitant use with other sodium phosphate bowel preparations.
## Adverse Effects
* **Common:** Abdominal cramping, nausea, vomiting, bloating, rectal irritation.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypernatremia, metabolic acidosis, dehydration, renal failure, cardiac arrhythmias, seizures, death. These are more likely with overuse, rapid administration, or in susceptible individuals.
## Key Drug Interactions
* **Other sodium-containing medications:** Increased risk of sodium and water retention.
* **Diuretics:** Increased risk of dehydration and electrolyte imbalances.
* **Drugs affected by fluid/electrolyte shifts:** Monitor closely.
## Monitoring
* Monitor for signs and symptoms of dehydration and electrolyte disturbances (e.g., nausea, vomiting, dizziness, muscle cramps, confusion, decreased urine output).
* Monitor renal function and electrolytes (especially phosphate, calcium, sodium) in patients with risk factors for imbalance or with repeated use.
## Clinical Pearls
* This product contains 4.4 g of elemental phosphorus and 4 g of sodium per 2.25 oz (66 mL) dose.
* Administer slowly and instruct the patient to retain the enema for the duration specified in the product labeling (typically 5-15 minutes).
* Ensure adequate hydration before and after administration.
* Do not use if the solution is cloudy or contains particles.
* Avoid use in the elderly or debilitated patients due to increased risk of adverse effects.
---
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before administering any medication.*
